Latest updates & what is forthcoming
February 9, 2021
Here's what to look out for --
Previews of unpublished data undergoing peer review:
-
drug prophylaxis for COVID-19 (including hydroxychloroquine and ivermectin)
-
anticipated by mid-February
-
-
antibodies and cellular therapies for treatment of COVID-19 (including convalescent plasma and bamlanivimab)
-
anticipated by mid-February
-
-
updated data on drug treatments for COVID-19
-
anticipated by early March
-
Peer-reviewed versions of the following:
-
adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir
We're also studying the credibility of trial preprints during the COVID-19 pandemic. Stay tuned for our study protocol!
Send us a message here if you have any questions about what is forthcoming!